Compare · PRPO vs RVTY
PRPO vs RVTY
Side-by-side comparison of Precipio Inc. (PRPO) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRPO and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $13.93B, about 252.2x PRPO ($55.2M).
- RVTY has been more active in the news (6 items in the past 4 weeks vs 2 for PRPO).
- RVTY has more recent analyst coverage (20 ratings vs 0 for PRPO).
- Company
- Precipio Inc.
- Revvity Inc.
- Price
- -
- -
- Market cap
- $55.2M
- $13.93B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 6
- Recent ratings
- 0
- 20
Precipio Inc.
Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
Latest PRPO
- Precipio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Precipio Announces Q2-2026 Financial Results
- Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Precipio Announces Q2-2026 Shareholder Update Call
- Director Valauri Christina Rizopoulos was granted 108 shares, increasing direct ownership by 2% to 5,628 units (SEC Form 4)
- Director Cossman Jeffrey was granted 416 shares, increasing direct ownership by 3% to 16,549 units (SEC Form 4)
- Director Cohen David Seth was granted 520 shares, increasing direct ownership by 0.95% to 55,199 units (SEC Form 4)
- Precipio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
- Precipio to Present at the Planet MicroCap Las Vegas
Latest RVTY
- Director Michas Alexis P gifted 285 shares (SEC Form 4)
- Officer Goldberg Joel S gifted 27,785 shares and received a gift of 27,785 shares, decreasing direct ownership by 67% to 13,729 units (SEC Form 4)
- Officer Singh Prahlad R. gifted 67,286 shares and received a gift of 67,286 shares, decreasing direct ownership by 59% to 46,026 units (SEC Form 4)
- SEC Form 10-Q filed by Revvity Inc.
- Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Revvity Announces Financial Results for the Second Quarter of 2026
- Revvity Board Declares Quarterly Dividend
- Vice President and CAO Gonzales Anita sold $9,306 worth of shares (85 units at $109.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,201 units (SEC Form 4)
- Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026